Portfolio Companies – Page 12 – BioScience Managers

Adherium Annual Report

18th August 2020/in Adherium

Link to Full Report

CalciMedica Announces Peer-Reviewed Publication of Positive COVID-19 Data and Initiation of Blinded, Placebo-Controlled Trial of Auxora™ in Patients with Severe COVID-19 Pneumonia

18th August 2020/in Calcimedica

Link to Full Article Study published in Critical Care journal shows patients with severe COVID-19 pneumonia treated with Auxora and standard of care had substantially improved outcomes compared to patients on standard of care alone Clinical trial to enroll up to 400 patients at sites across the U.S., including California, Texas and Louisiana, is being […]

Adherium appoints Mr Geoff Feakes as Chief Technology Officer

5th August 2020/in Adherium

Link to Full Article Melbourne, Australia – 5 August 2020: Adherium Limited (ASX: ADR) a leader in digital inhaled device adherence, remote monitoring and data management solutions, has appointed Mr Geoff Feakes as Chief Technology Officer (CTO) leading the Company’s R&D and Innovation teams supporting Adherium’s revised business strategy. Mike Motion, Adherium CEO noted: “I […]

CalciMedica and EpiPharma Enter into Research Collaboration to Discover and Develop CRAC Channel Inhibitor Therapies

21st July 2020/in Calcimedica

Under the terms of the research collaboration agreement, CalciMedica will use EpiPharma’s state of the art Pre-clinical Drug Testing and Diagnostics Laboratory Platform to accelerate its drug discovery pipeline La Jolla, Calif., USA; Szeged and Budapest, Hungary July 15, 2020 – CalciMedica, a clinical-stage biotechnology company targeting calcium release-activated calcium (CRAC) channels for the treatment of […]

CalciMedica Announces Data Showing Auxora™ Substantially Improved Outcomes in Patients with Severe COVID-19 Pneumonia

16th July 2020/in Calcimedica

Link to Full Article Median time to recovery was more than two times faster for patients treated with Auxora plus standard of care compared to standard of care alone The percentage of patients requiring invasive mechanical ventilation was 2.8 times lower with Auxora plus standard of care compared to standard of care alone Treating 2.6 […]

Cleansing notice under section 708A of the Corporations Act 2001 (Cth)

30th June 2020/in Adherium

Link to Full Article Adherium Limited ACN 605 352 510 (Company) (ASX: ADR) has undertaken an allotment of fully paid ordinary shares (Shares) under its Employee Share Plan. Details of the allotment are contained in the Appendix 2A filed the Company on 30 June 2020. The Company gives notice pursuant to section 708A(5)(e) of […]

Saluda Medical Appoints Jim Schuermann as President and Robert Gaffney as Chief Operating Officer

9th June 2020/in Saluda Medical

Link to Full Article Strengthens corporate leadership as company moves toward global commercialization Artarmon, Australia – June 9, 2020 – Saluda Medical Pty Limited (“Saluda Medical”), a global neuromodulation company leading the development and commercialization of data-driven, personalized therapies for patients with debilitating neurological disorders, today announced the key leadership appointments of Jim Schuermann as President and Robert Gaffney as Chief Operating […]

CALCIMEDICA APPOINTS ROBERT N. WILSON, FORMER J&J VICE CHAIRMAN AS CO-CHAIRMAN OF THE BOARD OF DIRECTORS AND ERIC W. ROBERTS AS VICE CHAIRMAN

2nd June 2020/in Calcimedica

Former Johnson & Johnson Vice Chairman, Robert N. Wilson, joins CalciMedica as Co-Chairman Board Member, Eric W. Roberts, named Vice Chairman and Chairman of the Strategic Transactions and Finance Committee of the Board LA JOLLA, Calif., June 2, 2020 – CalciMedica Inc. (“CalciMedica” or the “Company), a clinical-stage biotechnology company targeting calcium release-activated calcium (CRAC) channels […]

CALCIMEDICA ANNOUNCES POSITIVE TOPLINE DATA FROM INTERIM ANALYSIS OF TRIAL EVALUATING AUXORA™ IN PATIENTS WITH SEVERE COVID-19 PNEUMONIA

28th May 2020/in Calcimedica

Link to Full Article Interim results showed Auxora plus standard of care improved time to recovery and reduced ventilator use in patients compared to standard of care alone LA JOLLA, Calif., May 28, 2020 – CalciMedica Inc. (“CalciMedica” or the “Company), a clinical-stage biotechnology company targeting calcium release-activated calcium (CRAC) channels for the treatment of acute […]

CALCIMEDICA RAISES $15 MILLION IN SERIES C FINANCING ROUND LED BY VALENCE LIFE SCIENCES

22nd May 2020/in Calcimedica

Link to Full Article Funds to support ongoing clinical trials in patients with COVID-19 pneumonia and commercial manufacturing of Auxora™ LA JOLLA, Calif., May 22, 2020 – CalciMedica Inc. (“CalciMedica” or the “Company), a clinical-stage biotechnology company targeting calcium release-activated calcium (CRAC) channels for the treatment of acute and severe inflammatory diseases, today announced it has […]

Pages